Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.945
+0.0951.07%
Volume:35.24M
Turnover:319.32M
Market Cap:103.06B
PE:22.46
High:9.235
Open:8.900
Low:8.870
Close:8.850
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.06
T/O Rate:0.31%
Dividend:0.34
Dividend Rate:3.78%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.34
PE(LYR):22.46
PS:2.81

Loading ...

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS
·
Jul 27

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

Stock News
·
Jul 27

CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan

Reuters
·
Jul 27

CSPC Pharmaceutical - Expects H1 2026 Profit Attributable to Owners of Rmb5.9 Bln–RMB6.2 Bln

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Expected Result Due to Significant Increase in Licence Fee Income, Others in Hy

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical Group Stock Falls 2.9% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 27

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy

MT Newswires Live
·
Jul 27

Movement Alert|CSPC PHARMA Declines 3.16% in Regular Trading, Trading at HK$8.3

Market Focus
·
Jul 27

CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval

Simply Wall St.
·
Jul 27

Hong Kong Stock Market Analysis: ChangXin IPO Pressure Weighs, Agricultural Inflation Risks Boost Related Stocks

Stock News
·
Jul 24

CSPC Pharma Gains NMPA Approval for Once-Monthly Paliperidone Palmitate Injection to Treat Schizophrenia

Bulletin Express
·
Jul 24

CSPC Pharma's Paliperidone Palmitate Injection Receives Market Approval

Stock News
·
Jul 24

CSPC Pharma Wins China Approval for Paliperidone Palmitate Schizophrenia Injection

Reuters
·
Jul 24

CSPC Pharmaceutical - Paliperidone Palmitate Injection Receives Marketing Approval

THOMSON REUTERS
·
Jul 24

CSPC Pharmaceutical Group Stock Rises 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 24

Movement Alert|CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus
·
Jul 24

CSPC Pharma Starts Phase 2 Trial of HPV Therapeutic Vaccine in China

MT Newswires Live
·
Jul 23

CSPC Pharma Launches Phase II Trial of mRNA Vaccine SYS6026 for HPV16/18-Related Cervical HSIL

Bulletin Express
·
Jul 22

CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong

Dow Jones
·
Jul 21

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20